sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients

Simple item page
dc.contributor.authorAçılan, Ceyda
dc.contributor.buuauthorUlukaya, Engin
dc.contributor.buuauthorYılmaz, Meryem
dc.contributor.buuauthorYılmaztepe Oral, Arzu
dc.contributor.buuauthorArı, Ferda
dc.contributor.buuauthorZık, Berrin
dc.contributor.buuauthorUrsavaş, Ahmet
dc.contributor.buuauthorTokullugil, Asuman Hatice
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyokimya Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Veterinerlik Fakültesi/Temel Bilimler Bölümü.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-6729-7908tr_TR
dc.contributor.orcid0000-0003-0463-6818tr_TR
dc.contributor.researcheridAAI-3169-2021tr_TR
dc.contributor.researcheridAAH-9810-2021tr_TR
dc.contributor.researcheridAAG-7012-2021tr_TR
dc.contributor.researcheridA-5841-2017tr_TR
dc.contributor.researcheridK-5792-2018tr_TR
dc.contributor.scopusid6602927353tr_TR
dc.contributor.scopusid57197051873tr_TR
dc.contributor.scopusid26425326300tr_TR
dc.contributor.scopusid24376085300tr_TR
dc.contributor.scopusid6507763192tr_TR
dc.contributor.scopusid8329319900tr_TR
dc.contributor.scopusid6507662010tr_TR
dc.date.accessioned2022-03-21T08:16:25Z
dc.date.available2022-03-21T08:16:25Z
dc.date.issued2010-10
dc.description.abstractThe Fas/Fas Ligand (FasL) system and survivin have counteracting roles in cell survival. Therefore, we explored the role of circulating soluble Fas (sFas) and the tissue levels of Fas and survivin with regard to response to chemotherapy in lung cancer patients. Serum samples from 52 lung cancer patients and 54 control subjects (19 benign lung disease and 35 healthy control subjects) were collected prior to and 24 and 48 h after chemotherapy. sFas was statistically significantly higher in the cancer group than that in the control groups (p < 0.001). Baseline (before chemotherapy) sFas values showed a statistically significant inverse correlation with overall survival (r = -0.599, p < 0.001). There was a significant increase in serum sFas levels 24 h after treatment (p < 0.05). Contrarily, tissue levels of Fas and survivin were not changed following the chemotherapy (p > 0,05). In conclusion, increased sFas may be an indicator of poor outcome in lung cancer patients. However, cisplatin-based chemotherapy may not be effective via neither the Fas/FasL system nor survivin pathway. Indeed, larger sample size is required for further evaluation.en_US
dc.identifier.citationUlukaya, E. vd. (2010). "sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients". Cell Biochemistry and Function, 28(7), 565-570.en_US
dc.identifier.endpage570tr_TR
dc.identifier.issn0263-6484
dc.identifier.issn1099-0844
dc.identifier.issue7tr_TR
dc.identifier.pubmed20941746tr_TR
dc.identifier.scopus2-s2.0-78650491590tr_TR
dc.identifier.startpage565tr_TR
dc.identifier.urihttps://doi.org/10.1002/cbf.1689
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/full/10.1002/cbf.1689
dc.identifier.urihttp://hdl.handle.net/11452/25212
dc.identifier.volume28tr_TR
dc.identifier.wos000283615200005tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.bapUludağ Üniversitesitr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalCell Biochemistry and Functionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectApoptosisen_US
dc.subjectLung canceren_US
dc.subjectsFasen_US
dc.subjectFasen_US
dc.subjectSurvivinen_US
dc.subjectChemotherapyen_US
dc.subjectSoluble fas levelen_US
dc.subjectPrognostic-significanceen_US
dc.subjectPoor-prognosisen_US
dc.subjectLigand-expressionen_US
dc.subjectBreast-canceren_US
dc.subjectSurvivin geneen_US
dc.subjectTumor-cellsen_US
dc.subjectSerumen_US
dc.subjectCD95en_US
dc.subjectBiochemistry & molecular biologyen_US
dc.subjectCell biologyen_US
dc.subject.emtreeCisplatinen_US
dc.subject.emtreeEtoposideen_US
dc.subject.emtreeFas antigenen_US
dc.subject.emtreeFas liganden_US
dc.subject.emtreeGemcitabineen_US
dc.subject.emtreeNavelbineen_US
dc.subject.emtreeSurvivinen_US
dc.subject.emtreeApoptosisen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCancer chemotherapyen_US
dc.subject.emtreeCell survivalen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman tissueen_US
dc.subject.emtreeLung canceren_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeOverall survivalen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProtein expressionen_US
dc.subject.emtreeProtein functionen_US
dc.subject.meshAgeden_US
dc.subject.meshAntigens, CD95en_US
dc.subject.meshAntineoplastic agentsen_US
dc.subject.meshCisplatinen_US
dc.subject.meshFas ligand proteinen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshLung neoplasmsen_US
dc.subject.meshMaleen_US
dc.subject.meshMicrotubule-associated proteinsen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPrognosisen_US
dc.subject.meshSurvival analysisen_US
dc.subject.meshTumor markers, biologicalen_US
dc.subject.scopusFas Ligand; Anti-Fas Monoclonal Antibody; Death Domain Receptorsen_US
dc.subject.wosBiochemistry & molecular biologyen_US
dc.subject.wosCell biologyen_US
dc.titlesFas levels increase in response to cisplatin-based chemotherapy in lung cancer patientsen_US
dc.typeArticle
dc.wos.quartileQ3 (Biochemistry & molecular biology)en_US
dc.wos.quartileQ4 (Cell biology)en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus